Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and ...

Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a ...

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...

Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...

Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.